A bid defense is where a CRO defends its sites and enrollment plan to the sponsor — and it is won or lost on one question: can these sites actually enroll this study? We hand you the answer that ends the debate: real, patient-level qualifying patient counts for every site, down to a number. Data, not vibes.
A bid defense — or bid defense meeting — is the meeting where a CRO presents and defends its proposal to a sponsor: the operational plan, the timeline, and above all the sites and investigators it will use to enroll the trial. In clinical research it is where the contract is won or lost, and it almost always turns on the same question the sponsor keeps pressing: can these sites actually enroll this study?
Sponsors have heard every confident enrollment promise. What moves the room is evidence — not that a site looks good on paper, but that a named investigator can reach a counted number of patients who actually qualify for this protocol. Bring that, and the enrollment question is answered before it’s asked.
Everyone brings a site list. We bring the evidence behind it — the part sponsors can’t argue with.
For every candidate site, the exact number of patients who meet your protocol’s criteria — under an investigator’s direct care and across their institution. Real, not inferred.
A shortlist of consistently high-performing principal investigators, scored on a measured track record — not a reputation list of the usual academic names.
Site selection built on real, national, patient-level evidence — so the sites you defend are the sites that will enroll.
Everything the sponsor needs to believe the enrollment plan — on one page, per site:
In a recent rare-disease program, protocol modeling on real patient-level data nearly tripled the eligible pool — then became a ranked list of the sites that could actually reach those patients, on one evidence base.
Six things that turn a bid defense meeting from a pitch into a proof.
Confirm real, protocol-qualifying patient counts per site — not therapeutic-area estimates or inferred figures.
Name the investigators and show a measured performance track record for each.
Rank the sites on evidence — patient access plus performance — not reputation.
Show the enrollment math: first-patient-in, the ramp, and how you reach the target.
Have contacts and startup readiness ready for every proposed site.
Bring the data that survives the toughest question a sponsor can ask: “prove it.”
What is a bid defense in clinical trials?
A bid defense is the meeting where a CRO presents and defends its proposal to a sponsor — above all the sites and investigators it will use to enroll the trial. It is where the contract is won or lost, and it usually turns on one question: can these sites actually enroll this study?
What happens in a bid defense meeting?
The CRO walks the sponsor through its operational plan, timeline, and site and enrollment strategy, then defends it against the sponsor’s questions. The sharpest scrutiny falls on whether the proposed sites and investigators can reach enough qualifying patients to hit the enrollment target.
How do you win a bid defense?
You win by answering the enrollment question with evidence instead of a promise: real, patient-level qualifying patient counts for each site, named investigators with a measured track record, and a site list ranked on data rather than reputation. Data, not vibes.
What data do you need for a bid defense?
Real-world, patient-level data: the exact number of protocol-qualifying patients each investigator can reach, a measured enrollment track record per investigator, and a defensible ranking of sites — down to a number, not therapeutic-area estimates or inferred figures.
What is the difference between a bid defense and feasibility?
Feasibility asks whether and where a trial can enroll; a bid defense is where a CRO defends that plan to win the contract. Feasibility produces the evidence; the bid defense is where you present it — the same real, patient-level data underpins both.
We will hand you the real, patient-level evidence a sponsor can’t argue with — the sites, the investigators, and the qualifying-patient counts behind them.